Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Copeland

Showing results (431-440 of 450) with videos related to

Pageof 45
Sort By:
Nucleic Acids Research|January 10, 2003
E-MSD: the European Bioinformatics Institute Macromolecular Structure DatabaseH Boutselakis, D Dimitropoulos, J Fillon, et al.
Progress in Cardiovascular Diseases|February 7, 2021
The need for exercise sciences and an integrated response to COVID-19: A position statement from the international HL-PIVOT networkMark A Faghy, Ross Arena, Lee Stoner, et al.
Gynecologic Oncology|August 16, 2017
An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experienceKate E Oliver, William E Brady, Michael Birrer, et al.
Gynecologic Oncology|August 25, 2023
Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancerSandro Pignata, Michael Bookman, Jalid Sehouli, et al.
Transplantation|October 3, 1999
Safety, tolerability and efficacy of cyclosporine microemulsion in heart transplant recipients: a randomized, multicenter, double-blind comparison with the oil based formulation of cyclosporine--results at six months after transplantationH J Eisen, R E Hobbs, S F Davis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 27, 2022
Phase III Randomized Trial of Maintenance Taxanes Versus Surveillance in Women With Advanced Ovarian/Tubal/Peritoneal Cancer: A Gynecologic Oncology Group 0212:NRG Oncology StudyLarry J Copeland, Mark F Brady, Robert A Burger, et al.
Pilot and Feasibility Studies|February 17, 2024
Supporting physical activity through co-production in people with severe mental ill health (SPACES): protocol for a randomised controlled feasibility trialGareth Jones, Laura Bailey, Rebecca J Beeken, et al.
Annals of Neurology|January 5, 2023
Monkeypox-Associated Central Nervous System Disease: A Case Series and ReviewKelli M Money, T Allen Barnett, Samuel Rapaka, et al.
Obstetrics and Gynecology|January 12, 2019
Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian CarcinomaPeter G Rose, James J Java, Ritu Salani, et al.
Lancet (London, England)|August 1, 2017
Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)Krishnansu S Tewari, Michael W Sill, Richard T Penson, et al.
Pageof 45

Showing results (431-440 of 450) with videos related to

Sort By:
Pageof 45
Nucleic Acids Research|January 10, 2003
E-MSD: the European Bioinformatics Institute Macromolecular Structure DatabaseH Boutselakis, D Dimitropoulos, J Fillon, et al.
Progress in Cardiovascular Diseases|February 7, 2021
The need for exercise sciences and an integrated response to COVID-19: A position statement from the international HL-PIVOT networkMark A Faghy, Ross Arena, Lee Stoner, et al.
Gynecologic Oncology|August 16, 2017
An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experienceKate E Oliver, William E Brady, Michael Birrer, et al.
Gynecologic Oncology|August 25, 2023
Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancerSandro Pignata, Michael Bookman, Jalid Sehouli, et al.
Transplantation|October 3, 1999
Safety, tolerability and efficacy of cyclosporine microemulsion in heart transplant recipients: a randomized, multicenter, double-blind comparison with the oil based formulation of cyclosporine--results at six months after transplantationH J Eisen, R E Hobbs, S F Davis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 27, 2022
Phase III Randomized Trial of Maintenance Taxanes Versus Surveillance in Women With Advanced Ovarian/Tubal/Peritoneal Cancer: A Gynecologic Oncology Group 0212:NRG Oncology StudyLarry J Copeland, Mark F Brady, Robert A Burger, et al.
Pilot and Feasibility Studies|February 17, 2024
Supporting physical activity through co-production in people with severe mental ill health (SPACES): protocol for a randomised controlled feasibility trialGareth Jones, Laura Bailey, Rebecca J Beeken, et al.
Annals of Neurology|January 5, 2023
Monkeypox-Associated Central Nervous System Disease: A Case Series and ReviewKelli M Money, T Allen Barnett, Samuel Rapaka, et al.
Obstetrics and Gynecology|January 12, 2019
Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian CarcinomaPeter G Rose, James J Java, Ritu Salani, et al.
Lancet (London, England)|August 1, 2017
Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)Krishnansu S Tewari, Michael W Sill, Richard T Penson, et al.
Pageof 45